Observational studyArthritis care & research2026
Trends in Opioid Prescriptions in Individuals With Axial Spondyloarthritis in the United States and United Kingdom in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data.
Observational study in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveProlonged opioid use occurs in 25% of individuals with axial spondyloarthritis (axSpA). Whether introduction of tumor necrosis factor inhibitors (TNFi) influenced secular trends in opioid prescription in axSpA is unknown. We examined opioid prescription trends in axSpA, relative to nonsteroidal anti-inflammatory drugs (NSAIDs) and TNFi, using two observational databases.
methodsWe used data from IQVIA Medical Research Database (IMRD), a UK electronic health records-based database from 2000 to 2020, and Merative MarketScan (MarketScan), a US administrative claims-based database from 2006 to 2021. We included adults (18-89 years, IMRD; 18-65 years, MarketScan) with axSpA. We calculated annual prescription rates for opioids, NSAIDs, and TNFi (only in MarketScan) and estimated percentage changes in annual prescription rates by medication class using joinpoint regression.
resultsWe included 1,689 individuals from IMRD (mean age 47 years; 74% male) and 18,858 individuals from MarketScan (mean age 45 years; 51% male). In IMRD, annual opioid prescription rates decreased by 2.5% (95% confidence interval [CI] -9.1 to 1.9) between 2001 and 2007, increased by 3.9% (95% CI -3.0 to 14.2) between 2007 and 2016, and decreased by 0.4% (95% CI -11.2 to 2.9) between 2016 and 2020. In MarketScan, annual opioid prescription rates decreased by 1.5% (95% CI -3.0 to 2.0) in 2008 to 2016 and decreased by 8.6% (95% CI -15.2 to -5.7) in 2016 to 2021. TNFi prescriptions increased by 1.8% (95% CI 1.1 to 2.5) in 2008 to 2021.
conclusionOpioid prescription rates remained stable over time in the United Kingdom, whereas they slightly decreased in the United States as TNFi uptake increased. These trends may reflect a US nationwide change in guidance for opioid prescriptions issued in 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.